Go to main content

R&D Story

GC Biopharma’s researchers
Continue to rise
To the challenge of saving lives.

Third-Generation Recombinant Factor VIII Treatment for Hemophilia

Greengene F

Greengene F is a third-generation gene recombination therapy for hemophilia A, successfully developed by GC Biopharma, marking the third time globally. This product embodies the excellent technological prowess and know-how of GC Biopharma. Phase three clinical trials have been completed in China, which resulted in product approval in 2021. GC Biopharma is also striving to develop next-generation hemophilia treatments that treat patients with hemophilia A and B and antibody-producing patients by targeting novel blood coagulation mechanisms. GC Biopharma plans to expand its pipeline of blood disorder treatments in the domestic market and increase its market share worldwide.

A representative photograph of developing a professional medicine.

World-Class Quality

Plasma Derivatives

GC Biopharma remains committed to improving the products that have already received government and market approval. This commitment ensures an improvement in quality and diversifying dosages and types. IVIG-SN, human normal immunoglobulin for immunodeficiency, has obtained approval in 15 countries worldwide and is receiving growing demand in South America and elsewhere. IVIG-SN successfully completed its Phase 3 clinical trial in the United States. GC Biopharma expects to launch IVIG-SN in the United States marketplace shortly.

A Pioneer in the Global Vaccine Market


GC Biopharma secured its technology to manufacture the world's third-ever hepatitis B vaccine, Hepavax-B (approved in 1983). The company developed the world's first vaccine for epidemic hemorrhagic fever, Hantavax (approved in 1990), and the world's second chickenpox vaccine, Suduvax (approved in 1993), solidifying its position as a vaccine specialist company. Barycela (varicella II vaccine), which boasts improved product quality and safety compared to Suduvax, obtained domestic approval in 2020 and achieved WHO PQ certification in February 2023. In 2009, GC Biopharma played a pivotal role in safeguarding the nation against the contagious H1N1 flu virus that swept the world, achieving this by developing and launching GCflu (trivalent seasonal flu vaccine, approved in 2009), Greenflu-S (novel influenza vaccine, approved in 2009), and Greenflu-S plus with immune-boosting properties (approved in 2010).

GC Biopharma's trivalent flu vaccine has obtained WHO PQ (prequalification) certification, which is required to participate in international bidding. This achievement marks the first time in Asia and the fourth time globally. The quadrivalent flu vaccine, GCflu Quadrivalent (approved in 2015), has expanded the range of prophylactic vaccination by including an additional strain of influenza B virus. This vaccine obtained WHO PQ certification for the first time in South Korea and the second time worldwide. Furthermore, GC Biopharma introduced a Td vaccine, (tetanus-diphtheria vaccine, approved in 2016) using local technologies for the first time. The company also strives to develop a new combined vaccine (Tdap) that safeguards against all three infections: tetanus, diphtheria, and pertussis. As a result, GC Biopharma boasts a robust pipeline of vaccines for various diseases. It will continue its efforts to meet international standards and strengthen its global presence, transcending domestic approval.

Oncology, Immunology, and Cell Therapy

In 2014, GC Biopharma achieved the development of Neulapeg, a treatment for neutropenia. Designed as a supplement for immunosuppressant chemotherapy, Neulapeg effectively mitigates the side effects of the treatment. Additionally, it offers a longer half-life compared to its first-generation counterpart. This advancement has enabled the Korean medical community to discontinue importing similar drugs from overseas. Furthermore, GC Biopharma is working on introducing an innovative antibody production technology and will continue researching and developing new candidate materials for immunotherapy for cancer patients. Its specialized subsidiaries are also helping the company strengthen its position in cell therapy, which is emerging as a new potential source of economic growth.

Restoring Hope to People
with Rare Diseases

Rare Disease Treatments

At GC Biopharma, we believe it is our duty to research and develop treatments for rare diseases. Despite how difficult they are to make or how limited their market prospect is, they play a crucial role in saving lives. The first sign of success started in 2012 and came in the form of Hunterase, a treatment for Hunter syndrome, a hereditary metabolic disorder known as mucopolysaccharidosis (MPS) type-II. Developed as the second Hunter syndrome treatment globally, Hunterase has helped reduce the financial burden on Korean patients and their families by replacing the more expensive imported alternative and significantly improving their quality of life. Under GC Biopharma's plan to bring this innovative drug to Hunter syndrome patients around the world; it has been introduced into eight South American and North African markets. Hunterase was approved in China in 2020. and it is currently under clinical trials in many countries.

A representative photograph of developing a professional medicine.

Future Strategy

GC Biopharma has been accumulating expertise in plasma derivatives, vaccines, and recombinant proteins. In the process, the company has made significant impact on treatment for patients and on public health. GC Biopharma is now ready to maximize and upgrade the values of its existing products, and engage in strategic R&D activities to further strengthen its pipeline of products against a wider range of diseases.


GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일